Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Reasonable Options for Initial Treatment of Parkinson Disease


The drugs levodopa and pramipexole both appear to be reasonable options as initial therapy for Parkinson disease, but they are associated with different efficacy and adverse effects, according to an article in the July issue of The Archives of Neurology, one of the JAMA/Archives journals.

Parkinson disease is a progressive neurologic disease. It is believed to be related to low levels of the important neurotransmitter (messenger) dopamine in certain parts of the brain. When the drug levodopa is taken orally, it crosses through the “blood-brain barrier” and is converted to dopamine. Another drug, carbidopa, is added to levodopa to prevent the breakdown of levodopa before it crosses into the brain. Pramipexole is one of several drugs that mimic the role of dopamine in the brain, causing the neurons to react as they would to dopamine.

The Parkinson Study Group conducted a multicenter, parallel-group, double-blind, randomized controlled trial to compare initial treatment with pramipexole vs. levodopa in early Parkinson disease, followed by levodopa supplementation, with respect to the development of motor complications, other adverse events, and functional and quality of life outcomes. Robert G. Holloway, M.D., M.P.H., of the University of Rochester, Rochester, N.Y., and colleagues reported the results for the Parkinson Study Group.

Patients with early Parkinson disease who required dopaminergic therapy (relating to nerve cells or fibers that employ dopamine as their neurotransmitter) to treat emerging disability enrolled in the study between October 1996 and August 1997. Among 301 patients, 151 were randomly assigned to receive 0.5 milligrams of pramipexole three times per day with levodopa placebo. The other 150 patients received 25/100 milligrams of carbidopa/levodopa three times per day with pramipexole placebo. Dosage was escalated during the first ten weeks for patients with ongoing disability. After that, the investigators were permitted to add open-label levodopa or other anti-Parkinsonian medications to treat ongoing or emerging disability. The patients were observed until August 2001.

“Initial pramipexole treatment resulted in a significant reduction in the risk of developing dyskinesias [uncontrollable body movements; 24.5 percent vs. 54 percent with initial treatment with levodopa] and wearing off [47 percent vs. 62.7 percent with initial treatment with levodopa],” the authors write.

Initial levodopa treatment resulted in a significant reduction in the risk of “freezing” of motor function [25.3 percent vs. 37.1 percent with initial treatment with pramipexole], the researchers report.

Initial treatment with levodopa also resulted in lower incidences of somnolence (sleepiness; 36 percent vs. 21 percent), and edema (excess fluid in the tissues; 42 percent vs. 15 percent) and provided for better symptomatic control, as measured by the Unified Parkinson Disease Rating Scale.

By 48 months, the occurrence of disabling dyskinesias was uncommon and did not significantly differ between the two groups. Both options resulted in similar quality of life.

“Pramipexole and levodopa are associated with different efficacy and adverse-effect profiles. These differences are insufficient to identify a preferred strategy; hence, both pramipexole and levodopa appear to be reasonable options as initial dopaminergic therapy in Parkinson disease,” the authors conclude.

“Long-term follow-up is needed to determine if either treatment strategy is superior to the other in terms of patient impairment, disability, or quality of life,” they write.

| newswise
Further information:

More articles from Health and Medicine:

nachricht Advanced analysis of brain structure shape may track progression to Alzheimer's disease
26.10.2016 | Massachusetts General Hospital

nachricht Indian roadside refuse fires produce toxic rainbow
26.10.2016 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

How nanoscience will improve our health and lives in the coming years

27.10.2016 | Materials Sciences

OU-led team discovers rare, newborn tri-star system using ALMA

27.10.2016 | Physics and Astronomy

'Neighbor maps' reveal the genome's 3-D shape

27.10.2016 | Life Sciences

More VideoLinks >>>